MaxCyte Collaborates with Be Biopharma for the Development of BCMs Programs
Tuesday, 2 April 2024, 12:37
MaxCyte Partners with Be Biopharma
In a recent strategic move, MaxCyte has partnered with Be Biopharma to bolster the development of BCMs programs. This collaboration is set to drive innovation and advancements in the biopharmaceutical landscape.
Access to Flow Electroporation Technology
Be Biopharma gains exclusive access to MaxCyte's cutting-edge Flow Electroporation technology, setting the stage for transformative developments in the field.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.